Top Industry Leaders in the MEA Colorectal Cancer Market
Latest Middle East and Africa Colorectal Cancer Companies Update
AstraZeneca Secured regulatory approval for Imfinzi (durvalumab) for the treatment of stage III colorectal cancer in several MEA countries. This expands access to a key checkpoint inhibitor therapy.
Roche Launched Elepsys (bevacizumab) in combination with chemotherapy for the treatment of metastatic colorectal cancer in several MEA markets. This provides another targeted therapy option for advanced disease
Johnson & Johnson Partnered with local healthcare institutions in Egypt and South Africa to implement training programs for colorectal cancer screening and diagnosis.
Merck KGaA Collaborating with regional oncology centers to establish clinical research networks for the development and evaluation of new colorectal cancer treatments in the MEA region.
List of Middle East and Africa Colorectal Cancer Key Companies in the Market
- Hoffmann-La Roche Ltd (Switzerland)
- Amgen Inc. (US)
- Novartis AG(Switzerland)
- Abbott (US)
- Beckman Coulter Inc. (US)
- Debiopharm Group (Switzerland)
- AbbVie Inc. (US)
- Bayer AG (Germany)